Metropolitan Life Insurance Company (MetLife)’s 10x Genomics TXG Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,624	Closed	-$838K	–	2675
2021 Q4	$838K	Buy	5,624 +17	+0.3%	+$2.6K	0.01%	1095
2021 Q3	$816K	Buy	+5,607	New	+$963K	0.01%	1114
2021 Q2	–	Sell	-4,174	Closed	-$755K	–	2883
2021 Q1	$755K	Sell	4,174 -187	-4%	-$32.3K	0.01%	1144
2020 Q4	$618K	Sell	4,361 -85	-2%	-$12.3K	0.01%	1229
2020 Q3	$554K	Buy	4,446 +124	+3%	+$13K	0.01%	1149
2020 Q2	$386K	Buy	+4,322	New	+$337K	0.01%	1396

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s TXG Position: Q1 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 5,624 shares — an estimated $838K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TXG in Q2 2020 and held it in 6 quarters. The position peaked at $838K in Q4 2021. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 5,624 10x Genomics shares in Q1 2022, an estimated $838K.
Metropolitan Life Insurance Company (MetLife) first reported a position in 10x Genomics in Q2 2020 and held it in 6 quarters.
Metropolitan Life Insurance Company (MetLife)'s 10x Genomics position peaked at $838K in Q4 2021.
314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.